Related Experiment Video
Updated: Sep 13, 2026
Intravital Microscopy of Leukocyte-endothelial and Platelet-leukocyte Interactions in Mesenterial Veins in Mice
Published on: August 13, 2015
Increased platelet-monocyte aggregates and cardiovascular disease in end-stage renal failure patients
Neil Ashman1, Marion G Macey, Stanley L Fan
1Department of Renal Medicine and Transplantation, The Royal London Hospital, Whitechapel, London E1 1BB, UK.
Insights
Platelet activation and platelet-monocyte aggregates are increased in dialysis patients, contributing to cardiovascular disease risk. Reduced leucocyte PSGL-1 expression is observed, suggesting a novel mechanism for atherosclerosis in end-stage renal disease.
Area of Science:
- Nephrology
- Cardiology
- Hematology
Background:
- End-stage renal disease (ESRD) patients face high cardiovascular disease (CVD) morbidity and mortality.
- Conventional risk factors do not fully explain excess CVD in ESRD, irrespective of dialysis type.
- Platelet activation and interactions are implicated in atherosclerosis in non-uraemic populations.
Purpose of the Study:
- To investigate platelet activation and platelet-leukocyte aggregates in ESRD patients on continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis.
- To explore the association between these markers and cardiovascular events in stable ESRD patients without pre-existing CVD.
Main Methods:
- Immunofluorescent flow cytometry assessed P-selectin (CD62P) on platelets and P-selectin glycoprotein ligand-1 (PSGL-1, CD162) on leukocytes.
- Platelet-neutrophil and platelet-monocyte aggregates were quantified.
- Platelet count and mean platelet component (MPC) measured platelet activation.
Main Results:
- Hemodialysis patients showed significantly increased platelet activation (MPC, CD62P) versus controls.
- Both CAPD and hemodialysis patients exhibited increased platelet-monocyte aggregates and reduced monocyte PSGL-1 expression.
- Elevated platelet-monocyte aggregates correlated with increased cardiovascular events in dialysis patients.
Conclusions:
- ESRD patients exhibit increased platelet-monocyte aggregates and reduced leukocyte PSGL-1 expression, regardless of dialysis modality.
- These findings suggest a novel mechanism for accelerated atherosclerosis in uraemic patients.
- This highlights a potential therapeutic target for reducing CVD risk in ESRD.
Background:
Atherosclerotic cardiovascular disease is a major cause of morbidity and mortality in patients with end-stage renal disease. This excess morbidity cannot be entirely explained by well-recognized conventional and novel risk factors alone, and occurs irrespective of dialysis modality. Recent evidence suggests that the activation of platelets and their interaction with circulating cells are important independent risk factors for atherosclerosis in non-uraemic patients. We therefore studied platelet activation and circulating platelet-leucocyte aggregates in stable patients without evidence of cardiovascular disease on continuous ambulatory peritoneal dialysis (CAPD) and haemodialysis and investigated an association with cardiovascular events.
Methods:
Immunofluorescent flow cytometry was used to measure the percentage of P-selectin- (CD62P) positive platelets, the percentage of platelet-neutrophil and platelet-monocyte aggregates, and the expression of the P-selectin ligand, P-selectin glycoprotein ligand-1 (PSGL-1, CD162) on leucocytes in haemodialysis and CAPD patients and normal controls. The platelet count and the mean platelet component (MPC, a measure of platelet activation) were determined on the ADVIATM 120 Haematology System (Bayer, NY).
Results:
Platelet activation as assessed by MPC or CD62P expression was significantly increased in haemodialysis but not CAPD patients compared with controls. Circulating platelet-monocyte aggregates were significantly increased in parallel with a significant reduction in PSGL-1 expression on monocytes in both patient groups compared with normal controls. The presence of higher platelet-monocyte aggregates in dialysis patients was associated with increased cardiovascular events.
Conclusion:
We describe increased platelet-monocyte aggregates with reduced leucocyte PSGL-1 expression in patients with end-stage renal disease irrespective of dialysis modality, associated with an increased risk of cardiovascular disease. These findings may suggest a novel mechanism by which accelerated atherosclerosis occurs in uraemic patients.
Related Concept Videos
01:26Coronary Artery Disease II: Pathophysiology
01:28Diabetic Nephropathy